Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05491512 · ClinicalTrials.gov registry record · Phase 2
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
A Phase 2 study of Human Papilloma Virus and Oropharyngeal Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
- 7
- Study locations
NCT05491512 is a Phase 2 study of Human Papilloma Virus and Oropharyngeal Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 121 participants, below the 619-participant average among 26 other Human Papilloma Virus trials with a reported enrollment target (80% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT05491512, a Phase 2 study of Human Papilloma Virus and Oropharyngeal Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to find out if lower doses of radiation may help reduce the side effects of radiation therapy in combination with standard-of-care chemotherapy in people with HPV-positive throat cancer. The chemotherapy drugs used in this study include cisplatin, carboplatin, and 5-fluorouracil (5- FU), paclitaxel and abraxane- (Albumin-bound Paclitaxel).
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- RADIATION Radiation
- DRUG 5-fluorouracil
- DIAGNOSTIC_TEST 18 F-FMISO PET/CT
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center at Suffolk-Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2022-08-04 |
| Est. Completion | 2026-08-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05491512
The ClinicalTrials.gov registry entry for NCT05491512 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 619-participant average among 26 other Human Papilloma Virus trials with a reported enrollment target (80% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Human Papilloma Virus appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT05491512 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05491512 about?
NCT05491512 is a clinical study titled "A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer". The purpose of this study is to find out if lower doses of radiation may help reduce the side effects of radiation therapy in combination with standard-of-care chemotherapy in people with HPV-positive throat cancer. The chemotherapy drugs used in this study include cisplatin, carboplatin, and 5-fluo...
What is the current status of trial NCT05491512?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2022-08-04. Estimated completion is 2026-08-04.
What conditions does trial NCT05491512 study?
This clinical trial studies the following conditions: Human Papilloma Virus, Oropharyngeal Cancer, Hpv, Oropharyngeal Carcinoma, Throat Cancer.
What interventions are being tested in trial NCT05491512?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Radiation (RADIATION), 5-fluorouracil (DRUG), 18 F-FMISO PET/CT (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05491512?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05491512 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papilloma Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
De-Escalation Therapy for Human Papillomavirus Negative Disease
COMPLETED · Phase 2
-
Candin Safety & Efficacy Study for the Treatment of Warts
COMPLETED · Phase 2
-
Avelumab for People With Recurrent Respiratory Papillomatosis
COMPLETED · Phase 2
-
Educate and Improve Underserved Populations' Uptake and Completion of the HPV Vaccine
RECRUITING · NA
-
PopSci CHW4CervixHealth
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.